Filing Details

Accession Number:
0001179110-18-010467
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-09 19:46:33
Reporting Period:
2018-08-07
Accepted Time:
2018-08-09 19:46:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1583107 Theravance Biopharma Inc. TBPH () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1302448 J Bradford Shafer C/O Theravance Biopharma Us, Inc.
901 Gateway Boulevard
South San Francisco CA 94080
Evp, Gen. Counsel, Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2018-08-07 1,818 $28.99 127,606 No 4 S Direct
Ordinary Shares Disposition 2018-08-07 4,127 $28.03 123,479 No 4 S Direct
Ordinary Shares Disposition 2018-08-08 25,355 $27.85 98,124 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. This transaction was executed in multiple trades at prices from $28.60 to $29.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed in multiple trades at prices from $28.015 to $28.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices from $27.63 to $28.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.